Biggest Seed, Series A-E and Venture Investments within Oncology December 2023.
View the report at the bottom of this page.
December 2023 Snapshot:
178 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 646,228,727.00 total true investment received in USA and EU within the Oncology sector in November 2023 across 47 different biotechs.
Some Notable True Oncology Investments
✅Anixa Biosciences - Undisclosed (Grant): Pre-clinical and Phase I for both vaccines and CAR-T
✅Bicara Therapeutics - $165,000,000 (Series C): completed dose escalation studies evaluating BCA101 as a single-agent and in combination with pembrolizumab - Phase II
✅ Lassen Therapeutics - $ 85,000,000 (Series B): entering pre-clinical development for oncology trial and 2x Phase I for other illnesses
✅ CarThera - $4,843,365 (Series B): 2x Pre-clinical, 2x Phase I, Phase II for oncology trials and Phase I for other illnesses
✅ Plus 20+ companies in the report.
Acquisitions
👉 Bristol Myers Squibb (NYSE: BMY) and RayzeBio , Inc. (NASDAQ: RYZB) announced a definitive merger agreement RayzeBio Press Release, December 26 th 2023
👉 PointBio acquisition has been completed with Lilly Lilly, Investor Page, December 27 th 2023
👉 Astellas Pharma acquires Propella Therapeutics Propella Tx, Media Page, December 21st 2023.(First announced 15 th November 2023)
👉 Theseus Pharmaceuticals, Inc.entered into a definitive merger agreement with Concentra Biosciences, LLC Theseus, IR December 22nd 2023
Full information on these acquisitions can be found in the report.
Click here for full report.
